Patents by Inventor Michael Wacker
Michael Wacker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150267207Abstract: Described herein are novel methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.Type: ApplicationFiled: October 11, 2013Publication date: September 24, 2015Applicant: GLYCOVAXYN AGInventors: Michael Wacker, Michael Kowarik, Fabiana Fernandez
-
Publication number: 20150238596Abstract: Provided herein is a bioconjugate comprising a carrier protein and a modified antigen of Escherichia coli, the O antigen 0121. Also provided herein are uses of said bioconjugate, such as the treatment and/or prevention of diseases caused by Salmonella enterica, including diseases caused by Salmonella enterica subspecies I serovar Typhi (S. typhi).Type: ApplicationFiled: September 10, 2013Publication date: August 27, 2015Applicant: GlycoVaxyn AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20150190492Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.Type: ApplicationFiled: August 18, 2014Publication date: July 9, 2015Applicant: GlycoVaxyn AGInventors: Michael Wacker, Charles Waechter
-
Publication number: 20150044254Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: ApplicationFiled: October 23, 2014Publication date: February 12, 2015Applicant: GLYCOVAXYN AGInventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
-
Publication number: 20150010592Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: ApplicationFiled: September 23, 2014Publication date: January 8, 2015Applicant: GLYCOVAXYN AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Patent number: 8895014Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: February 19, 2009Date of Patent: November 25, 2014Assignee: Glycovaxyn AGInventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
-
Publication number: 20140335127Abstract: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins. The metabolic apparatus preferably comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired protein.Type: ApplicationFiled: February 25, 2014Publication date: November 13, 2014Applicant: ETH ZÜRICHInventors: Markus Aebi, Michael Wacker
-
Patent number: 8871491Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: GrantFiled: May 4, 2011Date of Patent: October 28, 2014Assignee: Glycovaxyn AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Patent number: 8846342Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.Type: GrantFiled: November 16, 2010Date of Patent: September 30, 2014Assignee: GlycoVaxyn AGInventors: Michael Wacker, Charles Waechter
-
Patent number: 8703471Abstract: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins. The metabolic apparatus preferably comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired protein.Type: GrantFiled: July 21, 2008Date of Patent: April 22, 2014Assignee: ETH ZürichInventors: Markus Aebi, Michael Wacker
-
Publication number: 20130028926Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.Type: ApplicationFiled: November 16, 2010Publication date: January 31, 2013Applicant: GLYCOVAXYN AGInventors: Michael Wacker, Charles Waechter
-
Publication number: 20110274720Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: ApplicationFiled: May 4, 2011Publication date: November 10, 2011Applicant: GlycoVaxyn AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20110097357Abstract: The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: ApplicationFiled: February 19, 2009Publication date: April 28, 2011Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
-
Publication number: 20090279454Abstract: The invention relates to a method for creating a DHCP network device configuration, wherein the parameter allocation by a DHCP server is performed using Option 82, and the assignment for the IP address to be allocated to a network device is determined on the basis of the topological information. The topological information is provided to the DHCP server by the requesting device and a DHCP relay agent, and the relay agent acts on each DHCP message sent by a device in the network by means of an additional DHCP Option 82 and sends the messages via unicast to the DHCP server, whereas the standard DHCP message is forwarded. According to the invention, a network device sends, in addition to the regular DHCP discovers via MAC broadcast, DHCP messages via MAC multicast to a MAC multicast address, and from this MAC multicast sends unique information via unicast to the DHCP server by means of a DHCP relay agent, since the associated network device filters the multicast.Type: ApplicationFiled: July 22, 2008Publication date: November 12, 2009Inventors: Michael Wacker, Markus Rentschler, Dirk Mohl, Oliver Kleineberg
-
Publication number: 20090074798Abstract: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins. The metabolic apparatus preferably comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired protein.Type: ApplicationFiled: July 21, 2008Publication date: March 19, 2009Applicant: ETH ZurichInventors: Markus Aebi, Michael Wacker
-
Publication number: 20050287628Abstract: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins. The metabolic apparatus preferably comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired protein.Type: ApplicationFiled: March 5, 2003Publication date: December 29, 2005Inventors: Markus Aebi, Michael Wacker
-
Publication number: 20040265954Abstract: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins. The metabolic apparatus preferably comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired protein.Type: ApplicationFiled: March 5, 2003Publication date: December 30, 2004Inventors: Markus Aebi, Michael Wacker